Application of ketamine to treatment of major depressive disorder

Abstract

The invention provides an application of a combined drug composition of ketamine or S-(+)-ketamine or a pharmaceutically acceptable salt of ketamine or S-(+)-ketamine, and escitalopram or a pharmaceutically acceptable salt of escitalopram, to the preparation of drugs for treating major depressive disorder. The major depressive disorder can be major depressive disorder breaking out for the first time, major depressive disorder breaking out again or refractory depression. The invention furthermore provides an application of ketamine or S-(+)-ketamine or the pharmaceutically acceptable salt of ketamine or S-(+)-ketamine to the preparation of the drugs for treating the major depressive disorder, and a drug preparation containing ketamine or S-(+)-ketamine or the pharmaceutically acceptable salt of ketamine or S-(+)-ketamine, and escitalopram or the pharmaceutically acceptable salt of escitalopram. Ketamine and conventional antidepressants are used together; and a proper amount of ketamine is intravenously injected once at first day of start of treatment, so that the anti-depression effect of oral antidepressants can be effectively improved, the effect display lag period is remarkably shortened, and suicidal actions of patients can be remarkably reduced.

Description

technical field [0001] The present invention relates to the application of ketamine in treating major depressive disorder and the application of ketamine in preparing medicine for treating major depressive disorder. The invention also relates to the application of ketamine and citalopram in treating major depressive disorder. Background technique [0002] Major depressive disorder (MDD) is a common mental disorder that causes physical and mental disability (Kessler et al., 2005). Major depressive disorder is defined as a severe form of depressive episode not explained by psychotic disorder or bipolar disorder. A major depressive episode is characterized by at least five of the following criteria over a 2-week period: (1) depressed / sad mood or (2) loss of interest and pleasure, (3) apathy or apathy, (4) or Irritability,(5) and is often associated with changes in several autonomic nervous system functions, including sleep patterns, appetite or weight, motor agitation or retar...

AI Technical Summary

Problems solved by technology

[0007] During the marked effect lag period before the clinical efficacy of conventional antidepressants, patients are at risk of suicide. The current treatment drugs and drug regimens cannot solve this problem well. Therefore, it is still necessary to improve the efficacy of antidepressants and shorten the marked effect lag period. Medications and regimens to reduce suicidal behavior in the early stages of antidepressant treatment

Images